ClinicalTrials.gg
Status unknownNCT03407664Updated Mar 10, 2020

NHS AAA Screening Programme Data Linkage With HES and ONS Datasets

An observational study in AAA, sponsored by University of Leicester. Status unknown at 1 site in United Kingdom. Open to male participants aged 65 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-03-10.

Sponsored by University of Leicester · Observational

The sponsor has not verified this record recently (last verified Jan 2020), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000,000
Ages
65 Years to 65 Years
Sex
Male
01

Study summary

An abdominal aortic aneurysm (AAA) is a dilation of the aorta, defined as an aortic diameter of ≥3cm. It is a significant cause of death internationally and in England each year causes c.4,000 deaths with 8,000 patients undergoing preventative surgery. AAA are often asymptomatic and there is a latent period between development and rupture. This represents an opportunity to screen by ultrasound which has been shown in trials to reduce AAA related mortality by half.

In England this evidence is based on a randomised trial data from the late nineties, however, since these data were published the number of men identified with AAA has fallen to a current prevalence of just over 1%. Furthermore, similarly designed randomised trials in Western Australia demonstrated no meaningful differences in AAA or cardiovascular deaths. The first aim of our research is to follow men who have been screened for AAA in England in order to establish the medium (5 years) and long term (10+ years) impact of AAA screening on the risk of a AAA, cardiovascular and all-cause morbidity/mortality in a non-trial setting. Men with sub-aneurysms will be examined (Aorta=2.5-2.9cm) as several studies suggest this group is at risk of late rupture.

The role of patient pathways to improve uptake of the screening programme will be examined. Current data suggests that the most 'deprived' men in England are the least likely to turn up for screening but the most likely to have an abdominal aneurysm. Outcomes in this group will be analysed including the benefit of a new patient pathway to improve uptake nationally.

Lastly, several large studies have demonstrated that a larger aortic diameter may be associated with cardiovascular risk. The addition of aortic diameter to current risk prediction models could improve the accuracy of these models and will be examined.

Read the detailed description

An abdominal aortic aneurysm (AAA) is present in 5-10% of men aged between 65 and 79 years and may be defined as an abdominal aortic diameter 3cm or above. In 2013 the NHS AAA screening programme (NAAASP) was fully rolled out across England with the aim of reducing AAA mortality in men aged 65 and over, based on evidence that screening reduces AAA-related mortality, and is highly cost effective. Within NAAASP, men with a large AAA (≤5.5cm) are referred for consideration of surgery whilst men with small AAA (≥5.4cm) are referred into surveillance (3.0-4.4cm: 1 year surveillance, 4.5-5.4cm: 3 months surveillance) as per standard operating procedures. In England 284,583 men were offered ultrasound screening (2015-2016), however, the number of men identified with AAA was 2,549 at a cost of approximately £7,755,000. This highlights one of the main problems with AAA screening in that the majority of men screened do not have disease. This also brought the number of men within AAA surveillance to 13,104 whom do not require early surgery.

The incidence of AAA is falling in western populations likely secondary to a reduction in the number of individuals smoking cigarettes in addition to other pharmacological (increase in the use of anti-platelets and statins) and lifestyle (exercise) modifications. This reduction in the number of men with AAA raises the question of whether in the long term community AAA screening will remain cost effective, however, to examine cost effectiveness it is important to establish what happens to all men invited to AAA screening over time. One aspect of this is examining the long term outcomes of men who have an aortic diameter above 3.0cm whilst another highly debated topic is the outcome of men with an aortic diameter between 2.5-2.9cm which may be defined as sub-aneurysmal. This group of men have been demonstrated to be at risk of developing AAA in later life (over 10 years) and there is a risk that these discharged men later go on to be at risk of aneurysm rupture.

the study would also like to examine the impact of deprivation on uptake of the screening programme is England. Uptake of the screening programme in 2015-2016 was 85.4%, however this varies from 76.6% in Merseyside to 92.0% in less deprived parts of England. Previous studies have highlighted the association between social deprivation and poor uptake and pilot data from our study suggests that this deprived group are also more likely to have an abdominal aneurysm. This puts this group at great risk without the benefit of screening to prevent rupture. Within this study outcomes in this group (AAA related death, admission and all-cause mortality/morbidity) will be assessed in order to accurately assess the cost benefit of new patient pathways to improve AAA screening uptake in the most deprived group.

Lastly, over time NAAASP will detect a large number of patients with small aneurysms that will require regular surveillance. Patients with AAA are widely recognized to be at a higher cardiovascular risk then the general population for example one recent systematic review identified a strong link between cardiovascular death and time from diagnosis of small AAA with a 3% increased risk of cardiovascular mortality per year compared with the general population. Duncan and Colleagues also described long term outcomes of men screened for AAA in Scotland finding that the most common cause of death in those with AAA was cardiovascular disease and that this risk increases with aortic diameter. Increasing aortic diameter and poor cardiovascular outcomes have also been noted in several other large cohort studies.

Aortic Diameter may be an independent marker of cardiovascular risk that could improve the sensitivity of current cardiovascular risk prediction models used commonly in England. Screening may also be an opportunity to identify men at higher cardiovascular risk (both with an aneurysm and without) creating added benefit to the screening programme. None the less contemporary data suggests that cardiovascular risk is inadequately addressed in this high risk cohort and requires further study.

02

Conditions studied

  • AAA
03

In context

Lead sponsor

University of Leicester is the lead sponsor of 170 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 65 Years
Sexes eligible
Male
Sampling method
Probability sample

Study population

Men screened for AAA within the NHS AAA Screening programme in England for the period covering 2013-2017; specifically, screening years 2013/14, 2014/15, 2015/16 and 2016/17.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All men invited to the NHS AAA screening programme in England between the period of 2013-2017
  2. Aged 65 years of age at the time of their invitation to the NHS AAA screening programme
  3. All men who have consented for their data to be used for the purposes of research

Exclusion criteria

Exclusion Criteria:

  • 1. All men who do not consent for their data to be used for the purposes of research
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Men Screened for AAA in England

    Men invited into the NHS AAA Screening programme in England in the years 2013-2017.

    Other: this field is not applicable

Interventions

  • Otherthis field is not applicable

    We will not be testing an intervention. Only the long term outcomes of men screened for AAA in England.

06

What researchers measure

Primary outcomes

  1. AAA related mortality in men invited for AAA screening

    Mortality

    Time frame: 10 years

  2. AAA related morbidity in men invited for AAA screening

    Admissions to Hospital

    Time frame: 10 years

Secondary outcomes

  1. Medium term mortality

    Mortality (number of deaths)

    Time frame: 5 years

  2. Cardiovascular risk in men screened for AAA

    Combined events (mortality and morbidity)

    Time frame: 10 years

  3. Medium term morbidity

    Admissions to Hospital

    Time frame: 5 years

07

Study locations

1 site
  • University of Leicester
    Leicester, LE3 9QP, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Data will be anonymised and no patient data will be passed outside of the research group. Results will be published in the usual way.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2020; primary completion for Jan 2021, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2017
First posted
Jan 23, 2018
StartEst.
Jul 1, 2020
Primary completionEst.
Jan 1, 2021
CompletionEst.
Jan 1, 2021
Last update
Mar 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03407664
Responsible party
Sponsor
First posted
Jan 23, 2018
Start date
Jul 1, 2020 (estimated)
Primary completion
Jan 1, 2021 (estimated)
Completion
Jan 1, 2021 (estimated)
Last update
Mar 10, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion